Product Description
Mechanisms of Action: CDK Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Eisai
Company Location: BUNKYO-KU TOKOYO 112 M0
Company CEO: Haruo Naito
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for Indisulam](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Colorectal Cancer|Breast Cancer|Gastrointestinal Cancer|Adenocarcinoma|Melanoma|Renal Cell Carcinoma|Preleukemia|Myelodysplastic Syndrome
Phase 1: Oncology Solid Tumor Unspecified|Gastrointestinal Cancer|Lung Cancer|Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
NCI-2012-02065 | P2 |
Completed |
Myelodysplastic Syndrome|Preleukemia |
2017-06-07 |
|
E7070-A001-106 | P1 |
Completed |
Lung Cancer|Gastrointestinal Cancer|Pancreatic Cancer |
2013-03-01 |
39% |
E7070-J081-217 | P2 |
Terminated |
Gastrointestinal Cancer |
2006-07-01 |
|
2004-002597-33 | P2 |
Completed |
Colorectal Cancer |
2006-01-10 |